Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer Market
The global Hormone Refractory Prostate Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hormone Refractory Prostate Cancer Scope and Market Size
Hormone Refractory Prostate Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
...
Hormone Refractory Prostate Cancer Breakdown Data by Type
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Hormone Refractory Prostate Cancer Breakdown Data by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Market Analysis and Insights: Global Hormone Refractory Prostate Cancer Market
The global Hormone Refractory Prostate Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hormone Refractory Prostate Cancer Scope and Market Size
Hormone Refractory Prostate Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Prostate Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
...
Hormone Refractory Prostate Cancer Breakdown Data by Type
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Hormone Refractory Prostate Cancer Breakdown Data by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
1.4 Market by Type
1.4.1 Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Hormonal Therapy
1.4.4 Immunotherapy
1.4.5 Radiation Therapy
1.4.6 Surgery
1.5 Market by Application
1.5.1 Global Hormone Refractory Prostate Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer Market Perspective (2015-2026)
2.2 Global Hormone Refractory Prostate Cancer Growth Trends by Regions
2.2.1 Hormone Refractory Prostate Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hormone Refractory Prostate Cancer Historic Market Share by Regions (2015-2020)
2.2.3 Hormone Refractory Prostate Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hormone Refractory Prostate Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key Hormone Refractory Prostate Cancer Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer Players by Market Size
3.1.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue (2015-2020)
3.1.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hormone Refractory Prostate Cancer Market Concentration Ratio
3.2.1 Global Hormone Refractory Prostate Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer Revenue in 2019
3.3 Hormone Refractory Prostate Cancer Key Players Head office and Area Served
3.4 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
3.5 Date of Enter into Hormone Refractory Prostate Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2015-2020)
4.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
5.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size (2015-2020)
6.2 Hormone Refractory Prostate Cancer Key Players in North America (2019-2020)
6.3 North America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
6.4 North America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size (2015-2020)
7.2 Hormone Refractory Prostate Cancer Key Players in Europe (2019-2020)
7.3 Europe Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
7.4 Europe Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
8 China
8.1 China Hormone Refractory Prostate Cancer Market Size (2015-2020)
8.2 Hormone Refractory Prostate Cancer Key Players in China (2019-2020)
8.3 China Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
8.4 China Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hormone Refractory Prostate Cancer Market Size (2015-2020)
9.2 Hormone Refractory Prostate Cancer Key Players in Japan (2019-2020)
9.3 Japan Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
9.4 Japan Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hormone Refractory Prostate Cancer Market Size (2015-2020)
10.2 Hormone Refractory Prostate Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
11 India
11.1 India Hormone Refractory Prostate Cancer Market Size (2015-2020)
11.2 Hormone Refractory Prostate Cancer Key Players in India (2019-2020)
11.3 India Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
11.4 India Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hormone Refractory Prostate Cancer Market Size (2015-2020)
12.2 Hormone Refractory Prostate Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
12.4 Central & South America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Astellas Inc
13.1.1 Astellas Inc Company Details
13.1.2 Astellas Inc Business Overview
13.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
13.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2015-2020))
13.1.5 Astellas Inc Recent Development
13.2 Sanofi S.A
13.2.1 Sanofi S.A Company Details
13.2.2 Sanofi S.A Business Overview
13.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
13.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.2.5 Sanofi S.A Recent Development
13.3 Dendreon Corporation, Bayer AG
13.3.1 Dendreon Corporation, Bayer AG Company Details
13.3.2 Dendreon Corporation, Bayer AG Business Overview
13.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
13.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.3.5 Dendreon Corporation, Bayer AG Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
13.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer Revenue
1.4 Market by Type
1.4.1 Global Hormone Refractory Prostate Cancer Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Hormonal Therapy
1.4.4 Immunotherapy
1.4.5 Radiation Therapy
1.4.6 Surgery
1.5 Market by Application
1.5.1 Global Hormone Refractory Prostate Cancer Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Specialty Clinics
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hormone Refractory Prostate Cancer Market Perspective (2015-2026)
2.2 Global Hormone Refractory Prostate Cancer Growth Trends by Regions
2.2.1 Hormone Refractory Prostate Cancer Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hormone Refractory Prostate Cancer Historic Market Share by Regions (2015-2020)
2.2.3 Hormone Refractory Prostate Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hormone Refractory Prostate Cancer Market Growth Strategy
2.3.6 Primary Interviews with Key Hormone Refractory Prostate Cancer Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hormone Refractory Prostate Cancer Players by Market Size
3.1.1 Global Top Hormone Refractory Prostate Cancer Players by Revenue (2015-2020)
3.1.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Players (2015-2020)
3.1.3 Global Hormone Refractory Prostate Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hormone Refractory Prostate Cancer Market Concentration Ratio
3.2.1 Global Hormone Refractory Prostate Cancer Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer Revenue in 2019
3.3 Hormone Refractory Prostate Cancer Key Players Head office and Area Served
3.4 Key Players Hormone Refractory Prostate Cancer Product Solution and Service
3.5 Date of Enter into Hormone Refractory Prostate Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hormone Refractory Prostate Cancer Historic Market Size by Type (2015-2020)
4.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
5.2 Global Hormone Refractory Prostate Cancer Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hormone Refractory Prostate Cancer Market Size (2015-2020)
6.2 Hormone Refractory Prostate Cancer Key Players in North America (2019-2020)
6.3 North America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
6.4 North America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer Market Size (2015-2020)
7.2 Hormone Refractory Prostate Cancer Key Players in Europe (2019-2020)
7.3 Europe Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
7.4 Europe Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
8 China
8.1 China Hormone Refractory Prostate Cancer Market Size (2015-2020)
8.2 Hormone Refractory Prostate Cancer Key Players in China (2019-2020)
8.3 China Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
8.4 China Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hormone Refractory Prostate Cancer Market Size (2015-2020)
9.2 Hormone Refractory Prostate Cancer Key Players in Japan (2019-2020)
9.3 Japan Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
9.4 Japan Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hormone Refractory Prostate Cancer Market Size (2015-2020)
10.2 Hormone Refractory Prostate Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
11 India
11.1 India Hormone Refractory Prostate Cancer Market Size (2015-2020)
11.2 Hormone Refractory Prostate Cancer Key Players in India (2019-2020)
11.3 India Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
11.4 India Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hormone Refractory Prostate Cancer Market Size (2015-2020)
12.2 Hormone Refractory Prostate Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Hormone Refractory Prostate Cancer Market Size by Type (2015-2020)
12.4 Central & South America Hormone Refractory Prostate Cancer Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Astellas Inc
13.1.1 Astellas Inc Company Details
13.1.2 Astellas Inc Business Overview
13.1.3 Astellas Inc Hormone Refractory Prostate Cancer Introduction
13.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer Business (2015-2020))
13.1.5 Astellas Inc Recent Development
13.2 Sanofi S.A
13.2.1 Sanofi S.A Company Details
13.2.2 Sanofi S.A Business Overview
13.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Introduction
13.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.2.5 Sanofi S.A Recent Development
13.3 Dendreon Corporation, Bayer AG
13.3.1 Dendreon Corporation, Bayer AG Company Details
13.3.2 Dendreon Corporation, Bayer AG Business Overview
13.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Introduction
13.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.3.5 Dendreon Corporation, Bayer AG Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Introduction
13.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
